Atul Deshpande is the Chief Strategy Officer at Peptilogics Inc., responsible for overall corporate strategy and business development.
Before joining Peptilogics, he was the CEO of IMMEDIATE Therapeutics, a clinical stage biotech company developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes (ACS).
Prior to IMMEDIATE Therapeutics, Atul was the Chief Strategy Officer and Head, US Operations of Harbour BioMed (HBM). Atul was responsible for building the company’s short- and long-term strategy and portfolio along with a robust execution plan. In 2020, he contributed to raising 2 VC funding rounds and taking the company public in the HK stock exchange raising a total of $400M.
Before HBM, Atul served as the Global Operations Head for the Dupixent Franchise with Sanofi. He led the operations, including marketing, market access, supply chain, to launch Dupixent in 52 markets across the world for Atopic Dermatitis and in major markets for Asthma. He also headed Asia Pacific R&D strategy in China. Before Sanofi, Atul worked as a management consultant for 9 years on projects across the value chain of pharma.
Atul holds a Ph.D. in Neuroscience from UCI and MBA from Cranfield University.
Before joining Peptilogics, he was the CEO of IMMEDIATE Therapeutics, a clinical stage biotech company developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes (ACS).
Prior to IMMEDIATE Therapeutics, Atul was the Chief Strategy Officer and Head, US Operations of Harbour BioMed (HBM). Atul was responsible for building the company’s short- and long-term strategy and portfolio along with a robust execution plan. In 2020, he contributed to raising 2 VC funding rounds and taking the company public in the HK stock exchange raising a total of $400M.
Before HBM, Atul served as the Global Operations Head for the Dupixent Franchise with Sanofi. He led the operations, including marketing, market access, supply chain, to launch Dupixent in 52 markets across the world for Atopic Dermatitis and in major markets for Asthma. He also headed Asia Pacific R&D strategy in China. Before Sanofi, Atul worked as a management consultant for 9 years on projects across the value chain of pharma.
Atul holds a Ph.D. in Neuroscience from UCI and MBA from Cranfield University.
Speaking In
10:30 AM - 10:45 AM
Wednesday, June 7
